CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Steris Q2 adjusted EPS beats; fiscal 2027 outlook lifted

By Reuters News


Overview

  • The infection prevention firm's fiscal Q2 revenue rose 9% yr/yr, with 8% organic growth

  • Adjusted EPS for fiscal Q2 rose and beat analyst expectations

  • Company raised fiscal 2027 adjusted EPS outlook, citing solid performance and tariff refunds


Outlook

  • Company expects fiscal 2027 revenue growth of 7-8% as reported, 6-7% organic

  • STERIS raises fiscal 2027 adjusted EPS outlook to $11.35-$11.55 from $11.10-$11.30


Result Drivers

  • LIFE SCIENCES GROWTH - Co said Life Sciences segment revenue rose 18%, led by 53% growth in capital equipment and higher consumables and service revenue

  • TARIFF REFUNDS - Co said tariff refunds provided a $20 mln pre-tax benefit to quarterly results


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Adjusted EPS

Beat

$2.94

$2.68 (7 Analysts)

Q2 EPS

$2.19

Q2 Adjusted Net Income

Beat

$286.80 mln

$262.41 mln (6 Analysts)

Q2 Net Income

$213.70 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for STERIS plc is $269.50, about 16.5% above its November 3 closing price of $231.35


Reuters Recommended Reads

  • Nov 4 - UK's Smith & Nephew misses Q3 revenue estimates, cuts outlook on slower US orthopaedics market

  • Nov 4 - LivaNova Q3 revenue beats estimates on cardiopulmonary segment strength

  • Nov 4 - Zimmer Biomet Q3 sales beat estimates, raises FY outlook


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.